2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Baker Bros. Advisors Lp | — | 11,045,336 | Mar 7, 2025 |
| 667, L.P. | — | 11,045,336 | Mar 7, 2025 |
| Baker Bros. Advisors (GP) LLC | — | 11,045,336 | Mar 7, 2025 |
| Baker Brothers Life Sciences LP | — | 11,045,336 | Mar 7, 2025 |
| Baker Felix | — | 11,045,336 | Mar 7, 2025 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Feb 20, 2026 | Astley-Sparke Philip | Director | Neutral | 27.5 | -25,000 | -1.78% | ✗ | - |
| Dec 19, 2025 | Dec 19, 2025 | Patel Sushil | CEO | Neutral | 90.0 | +200,000 | 59.96% | ✗ | - |
| Dec 19, 2025 | Dec 19, 2025 | Xynos Konstantinos | Chief Medical Officer | Neutral | 90.0 | +60,000 | 42.95% | ✗ | - |
| Dec 19, 2025 | Dec 19, 2025 | Hill Emily Luisa | CFO | Neutral | 90.0 | +60,000 | 44.65% | ✗ | - |
| Dec 19, 2025 | Dec 19, 2025 | Sarchi Christopher | Chief Commercial Officer | Neutral | 90.0 | +35,000 | 28.43% | ✗ | - |
| Dec 19, 2025 | Dec 19, 2025 | Schwendenman Andrew | Chief Accounting Officer | Neutral | 90.0 | +10,000 | 14.64% | ✗ | - |
| Dec 9, 2025 | Dec 11, 2025 | Dhingra Kapil | Director | Sell | 26.3 | -3,169 | -100.00% | ✗ | $33K |
| Dec 2, 2025 | Dec 4, 2025 | Patel Sushil | CEO | Sell | 41.3 | -10,000 | -2.91% | ✓ | $111.3K |
| Nov 17, 2025 | Nov 19, 2025 | Sarchi Christopher | Chief Commercial Officer | Sell | 46.3 | -5,208 | -4.06% | ✗ | $47.4K |
| Nov 17, 2025 | Nov 19, 2025 | Xynos Konstantinos | Chief Medical Officer | Sell | 42.5 | -7,248 | -4.93% | ✗ | $66K |
| Aug 15, 2025 | Aug 19, 2025 | Hill Emily Luisa | CFO | Sell | 46.3 | -9,154 | -6.38% | ✗ | $49.2K |
| May 20, 2025 | May 22, 2025 | Astley-Sparke Philip | Director | Sell | 40.0 | -32,279 | -2.25% | ✗ | $260.2K |
| May 20, 2025 | May 22, 2025 | Xynos Konstantinos | Chief Medical Officer | Sell | 42.5 | -7,952 | -5.13% | ✗ | $64.1K |
| May 20, 2025 | May 22, 2025 | Schwendenman Andrew | Chief Accounting Officer | Sell | 46.3 | -3,287 | -4.59% | ✗ | $26.5K |
| May 20, 2025 | May 22, 2025 | Patel Sushil | CEO | Sell | 42.5 | -25,105 | -6.81% | ✗ | $202.3K |
| May 20, 2025 | May 22, 2025 | Hill Emily Luisa | CFO | Sell | 46.3 | -2,535 | -1.74% | ✗ | $20.4K |
| May 20, 2025 | May 22, 2025 | Sarchi Christopher | Chief Commercial Officer | Sell | 46.3 | -3,749 | -2.84% | ✗ | $30.2K |
| Apr 1, 2025 | Apr 3, 2025 | Peeples-Dyer Veleka | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Patel Sushil | CEO | Neutral | 90.0 | +166,667 | 82.50% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Pucci Paolo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Balachandran Madhavan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Xynos Konstantinos | Chief Medical Officer | Neutral | 90.0 | +45,000 | 40.95% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Dhingra Kapil | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | SLATTERY JOSEPH P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Hill Emily Luisa | CFO | Neutral | 90.0 | +45,000 | 44.53% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Weinand Dieter | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Sarchi Christopher | Chief Commercial Officer | Neutral | 90.0 | +45,000 | 51.70% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Oliger Christy J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2025 | Apr 3, 2025 | Schwendenman Andrew | Chief Accounting Officer | Neutral | 27.5 | -33,333 | -31.77% | ✗ | - |
| Mar 7, 2025 | GOLLER MICHAEL | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 5, 2025 | Mar 7, 2025 | BAKER BROS. ADVISORS LP | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 7, 2025 | BAKER BROS. ADVISORS LP | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Dec 16, 2024 | Dec 18, 2024 | Patel Sushil | CEO | Sell | 37.5 | -10,000 | -4.72% | ✓ | $124.2K |
| Nov 18, 2024 | Nov 20, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 42.5 | -7,246 | -6.19% | ✗ | $78.1K |
| Nov 18, 2024 | Nov 20, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | 42.5 | -5,207 | -5.64% | ✗ | $56.1K |
| Sep 4, 2024 | Sep 5, 2024 | Balachandran Madhavan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Sep 5, 2024 | Balachandran Madhavan | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 30, 2024 | Aug 30, 2024 | Astley-Sparke Philip | Chair | Neutral | 27.5 | -50,000 | -3.36% | ✗ | - |
| Aug 16, 2024 | Aug 19, 2024 | Hill Emily Luisa | CFO | Sell | 42.5 | -8,938 | -8.13% | ✗ | $91K |
| Jun 7, 2024 | Jun 10, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 25.0 | -15,881 | -11.94% | ✓ | $119.1K |
| May 16, 2024 | May 20, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | 46.3 | -2,218 | -2.35% | ✗ | $14.4K |
| May 16, 2024 | May 20, 2024 | Schwendenman Andrew | Chief Accounting Officer | Sell | 46.3 | -2,298 | -5.67% | ✗ | $14.9K |
| May 16, 2024 | May 20, 2024 | Love Colin | COO | Sell | 42.5 | -17,615 | -2.22% | ✗ | $114K |
| May 16, 2024 | May 20, 2024 | Astley-Sparke Philip | Chair | Sell | 42.5 | -37,928 | -2.49% | ✗ | $245.4K |
| May 16, 2024 | May 20, 2024 | Coffin Robert | Director | Sell | 45.0 | -11,464 | -0.63% | ✗ | $74.2K |
| May 16, 2024 | May 20, 2024 | Patel Sushil | CEO | Sell | 42.5 | -20,194 | -8.70% | ✗ | $130.7K |
| May 16, 2024 | May 20, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 46.3 | -6,367 | -4.57% | ✗ | $41.2K |
| Apr 1, 2024 | Apr 3, 2024 | Peeples-Dyer Veleka | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Patel Sushil | CEO | Neutral | 90.0 | +83,335 | 55.98% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Pucci Paolo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Xynos Konstantinos | Chief Medical Officer | Neutral | 90.0 | +26,665 | 23.66% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Dhingra Kapil | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Hill Emily Luisa | CFO | Neutral | 90.0 | +26,665 | 32.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Sarchi Christopher | Chief Commercial Officer | Neutral | 90.0 | +22,225 | 30.76% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | SLATTERY JOSEPH P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Weinand Dieter | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Oliger Christy J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Levitsky Hyam | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2024 | Apr 3, 2024 | Schwendenman Andrew | Chief Accounting Officer | Neutral | 90.0 | +17,775 | 78.09% | ✗ | - |
| Nov 16, 2023 | Nov 17, 2023 | Xynos Konstantinos | Chief Medical Officer | Sell | 42.5 | -7,313 | -6.09% | ✗ | $79.9K |
| Nov 16, 2023 | Nov 17, 2023 | Sarchi Christopher | Chief Commercial Officer | Sell | 42.5 | -5,255 | -6.78% | ✗ | $57.4K |
| Sep 18, 2023 | Sep 20, 2023 | Hill Emily Luisa | CFO | Neutral | 90.0 | +83,330 | 100.00% | ✗ | - |
| Sep 20, 2023 | Hill Emily Luisa | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Sep 11, 2023 | Sep 13, 2023 | Esposito Pamela | Chief Business Officer | Sell | 45.0 | -5,658 | -1.06% | ✓ | $113.2K |
| Aug 22, 2023 | Aug 24, 2023 | Esposito Pamela | Chief Business Officer | Sell | 30.0 | -18,600 | -6.59% | ✓ | $372.2K |
| Aug 11, 2023 | Aug 15, 2023 | Esposito Pamela | Chief Business Officer | Sell | 51.3 | -1,400 | -0.53% | ✓ | $28K |
| Jul 26, 2023 | Sarchi Christopher | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jul 10, 2023 | Jul 11, 2023 | Esposito Pamela | Chief Business Officer | Sell | 30.0 | -20,000 | -7.06% | ✓ | $431.5K |
| Jun 13, 2023 | Jun 15, 2023 | Lewis Tanya | Chief Dev. Op. Officer | Sell | 26.3 | -12,860 | -8.68% | ✓ | $309.4K |
| Jun 13, 2023 | Jun 15, 2023 | Patel Sushil | Chief Strategy Officer | Sell | 37.5 | -5,698 | -3.69% | ✓ | $137K |
| Jun 1, 2023 | Jun 5, 2023 | Peeples-Dyer Veleka | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 5, 2023 | Peeples-Dyer Veleka | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 18, 2023 | Schwendenman Andrew | Chief Accounting Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 16, 2023 | May 18, 2023 | Patel Sushil | Chief Strategy Officer | Sell | 40.0 | -15,575 | -9.15% | ✗ | $281.1K |
| May 16, 2023 | May 18, 2023 | Coffin Robert | President | Sell | 47.5 | -7,861 | -0.43% | ✗ | $141.9K |
| May 16, 2023 | May 18, 2023 | Lewis Tanya | Chief Dev. Op. Officer | Sell | 42.5 | -12,207 | -7.61% | ✗ | $220.3K |
| May 16, 2023 | May 18, 2023 | Love Colin | COO | Sell | 42.5 | -10,775 | -1.34% | ✗ | $194.5K |
| May 16, 2023 | May 18, 2023 | Franchi Jean M. | CFO | Sell | 42.5 | -11,351 | -8.10% | ✗ | $204.9K |
| May 16, 2023 | May 18, 2023 | Xynos Konstantinos | Chief Medical Officer | Sell | 48.8 | -771 | -0.64% | ✗ | $13.9K |
| May 16, 2023 | May 18, 2023 | Esposito Pamela | Chief Business Officer | Sell | 42.5 | -5,966 | -2.21% | ✗ | $107.7K |
| May 16, 2023 | May 18, 2023 | Astley-Sparke Philip | CEO | Sell | 40.0 | -17,902 | -1.16% | ✗ | $323.1K |
| Apr 1, 2023 | Apr 4, 2023 | Slootweg Hugo Alexander | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Pucci Paolo | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Dhingra Kapil | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | SLATTERY JOSEPH P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Levitsky Hyam | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Weinand Dieter | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Oliger Christy J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Esposito Pamela | Chief Business Officer | Neutral | 90.0 | +40,000 | 17.44% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Xynos Konstantinos | Chief Medical Officer | Neutral | 90.0 | +50,000 | 70.62% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Franchi Jean M. | CFO | Neutral | 90.0 | +45,000 | 47.32% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Love Colin | COO | Neutral | 85.0 | +40,000 | 5.22% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Lewis Tanya | Chief Dev. Op. Officer | Neutral | 90.0 | +40,000 | 33.23% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Patel Sushil | Chief Strategy Officer | Neutral | 90.0 | +40,000 | 30.73% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Coffin Robert | President | Neutral | 82.5 | +45,000 | 2.51% | ✗ | - |
| Apr 1, 2023 | Apr 4, 2023 | Astley-Sparke Philip | CEO | Neutral | 90.0 | +142,100 | 10.14% | ✗ | - |
| Dec 9, 2022 | Dec 13, 2022 | Esposito Pamela | Chief Business Officer | Sell | 30.0 | -15,000 | -6.14% | ✓ | $375.5K |
| Dec 1, 2022 | Dec 5, 2022 | Xynos Konstantinos | Chief Medical Officer | Neutral | 90.0 | +17,500 | 32.83% | ✗ | - |
| Dec 5, 2022 | Xynos Konstantinos | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 16, 2022 | May 18, 2022 | Love Colin | COO | Sell | 45.0 | -6,324 | -0.82% | ✗ | $92.3K |